GI Illness

Oral Prophylactic Therapy Designated Breakthrough Therapy for CDI Prevention

Oral Prophylactic Therapy Designated Breakthrough Therapy for CDI Prevention

By

The FDA granted Breakthrough Therapy designation to Synthetic Biologics' ribaxamase SYN-004 for Clostridium difficile infection prevention.

Intestinal Dysbiosis May Link ME/CFS With GI and Neurological Disturbances

Intestinal Dysbiosis May Link ME/CFS With GI and Neurological Disturbances

Findings indicate that dysbiotic features that are uniquely ME/CFS-associated may be masked by disturbances arising from the high prevalence of IBS co-morbidity in ME/CFS.

Community-based Risk Factors for <i>C difficile</i> Infection in Children

Community-based Risk Factors for C difficile Infection in Children

By

Community-associated C difficile infection in children was linked to the combination of commonly used antibiotics and exposure to the bacterium in the home and outpatient healthcare settings.

CDC Issues New Recommendations for Treating <i>Shigella</i> Infection

CDC Issues New Recommendations for Treating Shigella Infection

By

The CDC has issued an alert regarding new recommendations for the treatment of Shigella infection.

CDC Lists Top Pathogens for Foodborne Illnesses

CDC Lists Top Pathogens for Foodborne Illnesses

Researcher found that while Salmonella infections decreased, reported Yersinia, Cryptosporidium, and Shiga toxin-producing E coli infections increased.

Gastric Acid Suppression Linked With Increased Risk of Recurrent CDI

Gastric Acid Suppression Linked With Increased Risk of Recurrent CDI

By

A meta-analysis study shows patients who take gastric acid suppressants have a higher risk for recurrent Clostridium difficile infection.

Review of <i>Clostridium difficile</i> Vaccines in Development

Review of Clostridium difficile Vaccines in Development

Drs Kociolek and Shulman, from the division of infectious diseases at the Ann & Robert H. Lurie Children's Hospital of Chicago in Illinois, review all the current vaccine candidates in development for Clostridium difficile infection.

Clinical Guideline on Evaluating Abnormal Liver Chemistries

Clinical Guideline on Evaluating Abnormal Liver Chemistries

By

The American College of Gastroenterology released a set of guideline for evaluating abnormal liver chemistries.

Facilitating Care for Patients With Early Stage Hepatocellular Carcinoma

Facilitating Care for Patients With Early Stage Hepatocellular Carcinoma

By

Investigators proposed an algorithm to facilitate the decision-making process of clinical care for patients with very early hepatocellular carcinoma.

Acute Myocardial Infarction Common in Renal Transplant Recipients

Acute Myocardial Infarction Common in Renal Transplant Recipients

Acute STEMI accounted for 29.3% of renal transplant recipients admissions.

High Rate of Metronidazole Resistance Seen in <i>C difficile</i> Infection

High Rate of Metronidazole Resistance Seen in C difficile Infection

By

Antibiotic resistance to therapies for Clostridium difficile infection are common, and their patterns should be considered in algorithms designed to select therapies.

Severe CDI Treatment With Vancomycin Has Lower 30-Day Mortality Risk

Severe CDI Treatment With Vancomycin Has Lower 30-Day Mortality Risk

By

No difference in the risk of Clostridium difficile infection (CDI) recurrence observed with vancomycin or metronidazole but 30-day mortality risk was significantly lower among patients with severe CDI treated with vancomycin.

Fecal Microbiota Transplant Effective for <i>C difficile</i> in Pregnancy

Fecal Microbiota Transplant Effective for C difficile in Pregnancy

A 28-year-old pregnant woman who presented with recurrent C difficile infection underwent a successful fecal microbiota transplant at 18 weeks of gestation.

Strategies for Increasing Hepatocellular Carcinoma Screening

Strategies for Increasing Hepatocellular Carcinoma Screening

Outreach strategies doubled the percentage of patients with cirrhosis who underwent ultrasound screening for HCC.

Short-Duration Triple DAA for Chronic HCV With Portal Hypertension

Short-Duration Triple DAA for Chronic HCV With Portal Hypertension

By

Trial finds the combination of simeprevir, daclatasvir, and sofosbuvir generally safe and well tolerated in HCV patients with decompensated liver disease.

Diet and Exercise Reduces Portal Pressure in Patients With Cirrhosis

Diet and Exercise Reduces Portal Pressure in Patients With Cirrhosis

In overweight/obese patients with cirrhosis and portal hypertension, a 16-weeks of diet and moderate exercise were safe and reduced body weight and portal pressure.

GI Inflammation Linked to Type 1 Diabetes

GI Inflammation Linked to Type 1 Diabetes

Duodenal mucosa in type 1 diabetes present with disease-specific abnormalities and inflammation, according to researchers.

Oral Antibiotics as Effective as Fecal Transplant for <i>C difficile</i>

Oral Antibiotics as Effective as Fecal Transplant for C difficile

Results showed no real difference in outcomes when comparing fecal transplant and antibiotic treatment.

Is There a Link Between Enterovirus and Pediatric Type 1 Diabetes?

Is There a Link Between Enterovirus and Pediatric Type 1 Diabetes?

By

Frequent enterovirus infection has been linked to type 1 diabetes in children.

Elevated Bacterial Gastroenteritis Risk With Acid Suppression Drugs

Elevated Bacterial Gastroenteritis Risk With Acid Suppression Drugs

By

Higher rates of both Clostridium difficile- and Campylobacter- positive gastroenteritis were seen in both community and hospital settings.

<i>H pylori</i> Recurrence Low One Year After Eradication

H pylori Recurrence Low One Year After Eradication

Risk factors for recurrence were peptic ulcer, contact with infected people, and hospitalization.

GBS Screening Not Cost-Effective in Repeat Cesarean Delivery

GBS Screening Not Cost-Effective in Repeat Cesarean Delivery

By

Universal group B streptococci screening in women with a singleton pregnancy planning a repeat cesarean delivery may not be cost-effective in all populations.

Treating <i>C difficile</i> Through Fecal Microbiota Transplant Cost-Effective

Treating C difficile Through Fecal Microbiota Transplant Cost-Effective

Both fecal microbiota transplant and vancomycin resulted in improved quality of life and reduced costs in patients with Clostridium difficile.

Acute Hepatitis Case Due to Overconsumption of Energy Drink

Acute Hepatitis Case Due to Overconsumption of Energy Drink

By

A 50-year-old man presents with acute hepatitis due excessive energy drink consumption.

FDA Approves Vaxchora for Cholera

FDA Approves Vaxchora for Cholera

By

The CDC's Advisory Committee on Immunization Practices voted unanimously to recommend Vaxchora for US travelers to areas of active cholera transmission.

Antibiotic Use Limits Death in Cirrhosis, Upper GI Bleeding

Antibiotic Use Limits Death in Cirrhosis, Upper GI Bleeding

Timely antibiotic administration reduces 30-day mortality among patients with cirrhosis and upper gastrointestinal bleeding.

FDA: Zinplava Approved to Reduce Recurrence of <i>C difficile </i> Infection

FDA: Zinplava Approved to Reduce Recurrence of C difficile Infection

FDA has approved Zinplava™ (bezlotoxumab) injection to reduce the recurrence of C difficile infection in patients at high risk.

FDA: New Data for Avycaz in Complicated UTI To Be Reviewed

FDA: New Data for Avycaz in Complicated UTI To Be Reviewed

By

FDA has accepted a supplemental New Drug Application (sNDA) for Avycaz for the addition of new Phase 3 data to the label.

<i>C difficile</i> Resistance Altered by Dietary Zinc

C difficile Resistance Altered by Dietary Zinc

Excess dietary zinc was found to alter gut microbiota.

<i>C difficile</i> Risk Among Hospital Bed Occupants

C difficile Risk Among Hospital Bed Occupants

Nearly 600 patient pairs were found to have an increased risk of Clostridium difficile infection.

Sign Up for Free e-newsletters